Clinical relevance of Fas (APO-1/CD95) expression in laryngeal squamous cell carcinoma

Head and Neck

Volumn 23, Issue 8, 2001, Pages 646-652

  Jckel, Martin C ^a   Mitteldorf, Christina ^a   Schweyer, Stefan ^a   Fzesi, Lszl ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Apoptosis; Fas; Immune surveillance; Laryngeal squamous cell carcinoma

Indexed keywords

FAS ANTIGEN; PARAFFIN;

APOPTOSIS; ARTICLE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TISSUE SECTION;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DNA FRAGMENTATION; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LARYNGEAL NEOPLASMS; MALE; PARAFFIN EMBEDDING; STROMAL CELLS;

EID: 0034958543     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.1091     Document Type: Article

References (26)

1. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
2. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells
3. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer
4. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis
5. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma
6. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis
7. Heterogeneous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma
8. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
9. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
10. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
11. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
12. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance
13. Prognostic relevance of altered Fas (CD95)-system in human breast cancer
14. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer
15. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas
16. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms
17. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma
18. Localization of Fas antigen in oral squamous cell carcinoma
19. Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue
20. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas
21. Prognostic significance of p53/bcl-2 co-expression in patients with laryngeal squamous cell carcinoma
22. IFN-g-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells
23. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness
24. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95)
25. The molecular interaction of Fas and FAP-1
26. Inhibition of death receptor signals by cellular FLIP